Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896 AM2)

Inclusion Criteria:

- Each participant must have schizophrenia, diagnosed, confirmed and reconfirmed by
board-eligible or board certified psychiatrists with at least two years of
specialization in pediatric/adolescent psychiatric medicine.

- Each participant must be ≥12 years of age and <18 years of age.

- Each participant must have a minimum PANSS total score of 80.

- Each participant must have a score of at least 4 (moderate) on two or more of the
five items in the positive subscale of the PANSS (delusions, conceptual
disorganization, hallucinatory behavior, grandiosity, suspiciousness/ persecution) at
Screening and Baseline.

- Each participant must have a CGI-S scale score of ≥4 at Screening and Baseline.

- Each participant must taper off all prohibited psychotropic medications (including
antipsychotics, antidepressants, and mood stabilizers).

Exclusion Criteria:

- A participant must not have a diagnosis of schizoaffective disorder; schizophrenia of
residual subtype; schizophrenia of catatonic subtype, or schizophrenia with
"continuous," "single episode in partial remission," or "single episode in full
remission" course specifiers.

- A participant must not have a primary Axis I diagnosis other than schizophrenia and
must not have a comorbid Axis I diagnosis that is primarily responsible for current
symptoms and functional impairment.

- A participant must not have a known or suspected diagnosis of mental retardation or
organic brain disorder.

- A participant must not currently (within the past 6 months) meet the Diagnostic and
Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR^TM) criteria for
substance abuse or dependence (excluding nicotine).

- A participant must not be at imminent risk of self-harm or harm to others, in the
investigator's opinion based on clinical interview and responses provided on the
Columbia Suicide Severity Rating Scale (C-SSRS).